Company intelligence / Profile preview

AhR Pharmaceuticals

Madison, Wisconsin, United Statestracxn.com ↗

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

AhR Pharmaceuticals focused on developing ITE, a natural hormone acting as an agonist of the aryl hydrocarbon receptor (AHR), for cancer, obesity, and immune system disorders. The company’s lead program remained in preclinical development with promising early proof-of-concept data but did not advance to clinical trials before becoming inactive.

Therapeutic areas: OncologyEndocrinologyImmunology
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

ITE

Pre-clinical

Indications: Cancer

Partnerships

Wisconsin Alumni Research Foundation (WARF) – exclusive license for ITE intellectual property

Beyond the preview

Go deeper on AhR Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AhR Pharmaceuticals.

Explore the full profile